Relentlessly focused on advancing the treatment of inflammation and cancer
RAPT Therapeutics is a clinical-stage biopharmaceutical company driven by a bold mission—to treat inflammatory diseases and conquer cancer in our lifetime. Our cutting-edge science is fully focused on developing oral therapeutics that intelligently target key drivers of the immune system to transform the treatment of inflammation and cancer, and improve and empower countless lives. Join us in our quest.
RAPT Therapeutics Reports Second Quarter 2024 Financial Results
May 09, 2024
RAPT Therapeutics Reports First Quarter 2024 Financial Results
April 09, 2024
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
You are leaving RAPT.com to go to the eczema clinical trial study site.